New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.

Atrial fibrillation and atrial flutter have both an association with diabetes and increase individual mortality risk. Potential associations between arrhythmias and hyperglycemia include myocardial remodeling leading to inflammation and cardiac fibrosis, thus altering atrial electrical patterns. While this association has been identified, conflicting evidence exists regarding the use of antihyperglycemic therapy and its relation to increasing or decreasing arrythmia development. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors including empagliflozin, dapagliflozin, and canagliflozin, lower glucose levels by blocking reabsorption of glucose in the renal tubules. Additionally, SGLT-2 inhibitors may prevent development of arrhythmias by reducing patient body weight, blood pressure, blood glucose, epicardial adipose tissue, atrial dilation, and increasing serum magnesium levels. This presentation will review evidence related to the use of SGLT-2 inhibitors and prevention of arrhythmias.